Global Digital Pathology Market, 2017 Companies-To-Action

Collaborative Business Models Embracing Artificial Intelligence Application in Novel Disease Areas to Drive Market Growth

USD 3,000

* Required Fields

USD 3,000


Be the first to review this product

It is estimated that more than 19,000 pathologists would be needed to serve the US healthcare needs. However, the actual number is expected to be approximately 40% lesser. Similar trends are foreseen globally driven by aging population and widening application in areas such as cancer diagnostics, drug development, clinical trials, biomarker discovery, and companion diagnostics. Digital pathology can improve efficiency of pathologists by 10–15%, thereby helping the healthcare providers in filling such gaps. This factor is a key driver for the rapid growth in adoption of digital pathology solutions globally.

In April 2017, FDA approved the IntelliSite Pathology Solution from Royal Philips. This was the first digital pathology product for which any US manufacturer received approval for primary diagnostics purpose. An expected increase in regulatory approval for digital pathology systems for primary diagnostics will support the growth in demand for these systems.

To cater to the growing demand for digital pathology solutions, the industry has observed numerous partnerships, collaborations, and M&As. These strategies have been undertaken to expand product portfolio and deepen solution expertise while catering to changing customer demands.

Research Scope:
The key objectives of the companies-to-action for digital pathology study are to highlight current market dynamics, key market participants, customer segments, and evolving business opportunities. The study aims to identify both established enterprises and start-ups, which are capable of shaping the future through best practices implementation, visionary leadership, and innovation in business models.

Further, the study provides an analysis of companies segregated by hardware, software, services and storage. It covers business profile, key solution offerings, target customer segments, service differentiators, and future growth strategies.

The study also highlights growth opportunities, case study of notable market developments, key trends, mergers and acquisitions, for investment and collaboration opportunities.

Companies mentioned in the study are Agfa Healthcare, Corista, Definiens, Fimmic Oy, GE (Omnyx), Hamamatsu, Huron Digital Pathology, Indica Labs, Inspirata, Leica Biosystems, OptraSCAN, Pathcore, Philips, Proscia, Sectra, Sunquest, Visiopharm, Ventana Medical Systems, Roche, and 3D Histech.

Key questions this study will answer:
• How are digital pathology companies creating extraordinary value for stakeholders?
• Which are some unique companies that are introducing new and innovative solutions in the market?
• How do these companies intend to transform healthcare industry paradigms in the future? What is the impact of the external industry
environment on this market?
• What is their action plan and potential for growth?
• What are the current growth opportunities in digital pathology?
• What are some key success factors in the digital pathology market?
• Which are the companies with whom partnerships can be forged?

Table of Contents

1. Executive Summary
Scope and Segmentation
Key Findings
2. Companies-To-Action Overview
Companies-To-Action Value Creators
Threats & Opportunities
3. Digital Pathology Market Overview
Definition and Solution Segmentation
Impact of Key Market Influencers
Top 3 Trends and Vendor Strategies
C2A Targets Aligned with Top 3 Trends
4. Companies-To-Action Profiles
Value Chain Analysis
Benchmarking of Top Companies-To-Action
Indica Labs
Leica Biosystems
Ventana Medical Systems—Roche
Short Profiles of Digital Pathology Companies (1 of 2)
Short Profiles of Digital Pathology Companies (2 of 2)
5. Competitive Playbook
GE Healthcare and Omnyx—Case Study 1
GE Philips—Case Study 2
Key Mergers and Acquisitions
6. Growth Opportunities and Companies-to-Action
Top 5 Growth Opportunities
Strategic Imperatives for the Digital Pathology Market
7. The Last Word
Conclusion—Key Takeaway from the Companies-To-Action Analysis
Legal Disclaimer
8. Appendix
Comparative Matrix of Companies
9. The Frost & Sullivan Story
Interested in Full Access? Connect With Us


List of Figures & Charts

1. Digital Pathology Market: Key Segments, Global, 2017
2. Digital Pathology Market: Acquisitions and Partnerships by Philips, Global, 2015–2017
3. Digital Pathology Market: Mergers and Acquisitions, Global, 2010–2016
4. Digital Pathology Market: Solution Portfolio Comparative Matrix, Global, 2017

1. Digital Pathology Market: Companies-To-Action Value Creators, Global, 2017
2. Digital Pathology Market: Impact of Key Market Influencers, Global, 2017
3. Digital Pathology Market: C2A Targets Aligned with Top 3 Trends, Global, 2017
4. Digital Pathology Market: Value Chain Analysis, Global, 2017
5. Digital Pathology Market: Companies-To-Action, Key Areas to Focus, Global, 2017
6. Digital Pathology Market: GE Healthcare & Omnyx Joint Venture, Global, 2008–2016

digital pathology
digital pathology

Related Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.